Galenica has reported a record sales growth of 5.5% in 2025, driven by its expanding pharmacy network and the new Diagnostics segment, alongside a positive operational outlook following the acquisition of Labor Team.

Information on the Target

Galenica has demonstrated remarkable growth, with sales soaring 5.5% to reach CHF 4,135.6 million—marking the highest revenue ever recorded by the company. This growth is attributed to robust performance across all business segments, particularly the pharmacy and wholesale sectors. Additionally, the newly established 'Diagnostics' segment contributed positively to this upward trajectory, driven mainly by heightened demand for prescription medications, especially GLP-1-based weight loss products and dietary supplements.

CEO Marc Werner remarked on the sales figures, stating, 'Our broad-based positioning and the high level of integration within the network provide us the stability necessary for continued growth and innovation in Swiss healthcare.' With these positive developments, Galenica is poised to exceed its sales forecasts and anticipates an EBIT improvement of 10-12% for 2025, following the successful acquisition of Labor Team. The company also plans to maintain dividends at least at last year's levels.

Industry Overview in Switzerland

The pharmacy sector in Switzerland has witnessed significant growth, with pharmacies increasingly recognized as the primary healthcare contact for patients. Galenica expanded its pharmacy network by adding five new locations through strategic acquisitions,